Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP

Aviva Silbergeld; Beatrice Klinger; Ruth Keret; Rina Eshet; Antonio Selman Almonté; Zvi Laron

doi:10.3181/00379727-206-43769

Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP

Aviva Silbergeld, Beatrice Klinger, Ruth Keret, Rina Eshet, Antonio Selman Almonté, Zvi Laron

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Three Laron Syndrome (LS) siblings with a post growth hormone (GH) receptor defect for insulin-like growth factor-l (IGF-I) synthesis were found to have serum GH-binding protein (GHBP) levels normal for age. Treatment with recombinant IGF-I (150 μg/kg/day) decreased serum GHBP activity to 62% of the basal value (P < 0.001) in two of the sibs in 1 week and in the third sib after 3 months of therapy. Scatchard analysis of the binding of [¹²⁵I]human GH (hGH) to GHBP in patients' sera before and during therapy revealed affinity constants K_a = 1.55-1.80 × 10⁹M^-1, similar to that of sera from healthy subjects. Variations in binding are due to changes in the binding capacity. IGF-I may be a regulatory factor for serum GHBP activity in man.

Original language	English
Pages (from-to)	324-327
Number of pages	4
Journal	Experimental Biology and Medicine
Volume	206
Issue number	3
DOIs	https://doi.org/10.3181/00379727-206-43769
State	Published - 1 Jan 1994
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.3181/00379727-206-43769

Cite this

@article{62c09b4472474858baa4a380b762a6ae,

title = "Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP",

abstract = "Three Laron Syndrome (LS) siblings with a post growth hormone (GH) receptor defect for insulin-like growth factor-l (IGF-I) synthesis were found to have serum GH-binding protein (GHBP) levels normal for age. Treatment with recombinant IGF-I (150 μg/kg/day) decreased serum GHBP activity to 62% of the basal value (P < 0.001) in two of the sibs in 1 week and in the third sib after 3 months of therapy. Scatchard analysis of the binding of [125I]human GH (hGH) to GHBP in patients' sera before and during therapy revealed affinity constants Ka = 1.55-1.80 × 109M-1, similar to that of sera from healthy subjects. Variations in binding are due to changes in the binding capacity. IGF-I may be a regulatory factor for serum GHBP activity in man.",

author = "Aviva Silbergeld and Beatrice Klinger and Ruth Keret and Rina Eshet and Almont{\'e}, {Antonio Selman} and Zvi Laron",

year = "1994",

month = jan,

day = "1",

doi = "10.3181/00379727-206-43769",

language = "English",

volume = "206",

pages = "324--327",

journal = "Experimental Biology and Medicine",

issn = "0037-9727",

publisher = "Frontiers Media SA",

number = "3",

}

Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP. / Silbergeld, Aviva; Klinger, Beatrice; Keret, Ruth et al.
In: Experimental Biology and Medicine, Vol. 206, No. 3, 01.01.1994, p. 324-327.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP

AU - Silbergeld, Aviva

AU - Klinger, Beatrice

AU - Keret, Ruth

AU - Eshet, Rina

AU - Almonté, Antonio Selman

AU - Laron, Zvi

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Three Laron Syndrome (LS) siblings with a post growth hormone (GH) receptor defect for insulin-like growth factor-l (IGF-I) synthesis were found to have serum GH-binding protein (GHBP) levels normal for age. Treatment with recombinant IGF-I (150 μg/kg/day) decreased serum GHBP activity to 62% of the basal value (P < 0.001) in two of the sibs in 1 week and in the third sib after 3 months of therapy. Scatchard analysis of the binding of [125I]human GH (hGH) to GHBP in patients' sera before and during therapy revealed affinity constants Ka = 1.55-1.80 × 109M-1, similar to that of sera from healthy subjects. Variations in binding are due to changes in the binding capacity. IGF-I may be a regulatory factor for serum GHBP activity in man.

AB - Three Laron Syndrome (LS) siblings with a post growth hormone (GH) receptor defect for insulin-like growth factor-l (IGF-I) synthesis were found to have serum GH-binding protein (GHBP) levels normal for age. Treatment with recombinant IGF-I (150 μg/kg/day) decreased serum GHBP activity to 62% of the basal value (P < 0.001) in two of the sibs in 1 week and in the third sib after 3 months of therapy. Scatchard analysis of the binding of [125I]human GH (hGH) to GHBP in patients' sera before and during therapy revealed affinity constants Ka = 1.55-1.80 × 109M-1, similar to that of sera from healthy subjects. Variations in binding are due to changes in the binding capacity. IGF-I may be a regulatory factor for serum GHBP activity in man.

UR - http://www.scopus.com/inward/record.url?scp=0027931075&partnerID=8YFLogxK

U2 - 10.3181/00379727-206-43769

DO - 10.3181/00379727-206-43769

M3 - Article

C2 - 8016174

AN - SCOPUS:0027931075

SN - 0037-9727

VL - 206

SP - 324

EP - 327

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

IS - 3

ER -

Serum Growth Hormone-Binding Protein (GHBP) Activity is Decreased by Administration of Insulin-Like Growth Factor I in Three Laron Syndrome Siblings with Normal GHBP

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this